FindTrial
Sign In

Cis Platinum

DRUG6 trials

Sponsors

Wake Forest University Health Sciences, Kobe Minimally Invasive Cancer Center, Zhongshan Hospital Xiamen University, Dr. Victor H.F. Lee, The First Affiliated Hospital with Nanjing Medical University

Conditions

Esophageal Squamous Cell CarcinomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaLocally Advanced CarcinomaLocally Advanced Non-small Cell Lung CancerLung Cancer Stage IILung Cancer Stage IIINon Small Cell Lung Cancer

Phase 1

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
RecruitingNCT06494943
Fudan UniversityHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2024-06-26End: 2028-12-31Target: 27Updated: 2025-02-25

Phase 2

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
Active, not recruitingNCT03141359
Wake Forest University Health SciencesLung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Start: 2017-05-12End: 2027-07-01Updated: 2026-07-28
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
Not yet recruitingNCT04153734
Kobe Minimally Invasive Cancer CenterLocally Advanced Non-small Cell Lung Cancer
Start: 2019-12-01End: 2023-11-30Target: 21Updated: 2019-11-06
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
NCT04590625
Zhongshan Hospital Xiamen UniversityOvarian Cancer
Start: 2020-10-31End: 2023-12-31Target: 58Updated: 2020-10-19
Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
Not yet recruitingNCT05151588
Dr. Victor H.F. LeeSinonasal Carcinoma
Start: 2023-09-01End: 2027-08-31Target: 30Updated: 2023-02-28
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
NCT05469061
The First Affiliated Hospital with Nanjing Medical UniversityEsophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Start: 2022-01-01End: 2022-11-01Target: 17Updated: 2022-07-21

Related Papers

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
2025-10-11
Neoadjuvant IBI110 and sintilimab in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma.
Journal of Clinical Oncology2025-05-28
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
2024-11-2910 citations
Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.
2024-08-231 citations
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).
Journal of Clinical Oncology2024-06-051 citations
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).
Journal of Clinical Oncology2023-06-01
Phase II prospective trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation and adjuvant immunotherapy for locally-advanced non-small cell lung cancer (NSCLC): Planned toxicity analysis.
Journal of Clinical Oncology2020-05-204 citations